Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I9AR
|
|||
| Former ID |
DIB012069
|
|||
| Drug Name |
BMS-185857
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Terminated | [1] | |
| Company |
Bristol-Myers Squibb AG
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CAAX farnesyltransferase beta (FNTB) | Target Info | Modulator | [2] |
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Biosynthesis of antibiotics | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Reactome | Inactivation, recovery and regulation of the phototransduction cascade | |||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004901) | |||
| REF 2 | US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.